Abstract
Two novel cyclometalated iridium(III) complexes containing fluorinated phenylpyridine (TFPPy)2IrPic or phenylquinoline (TFPQ)2IrPic with pyridine-2-carboxylate as chelating ligands were synthesized and fully characterized. These complexes displayed hypoxia sensing and therapeutical activities. As hypoxia probes these two complexes achieved S/B ratio of 7.125; 8.156. Besides the anti-proliferation activities against Cisplatin-resistant cancer cells, radiosensitization effect with SER value 1.742–1.941 were observed even in radio-resistant cell lines after treatment with these complexes, mechanism confirmed via typical G2 phase arrest. Furthermore, the two complexes have shown antiviral activity against both HSV-1 and HSV-2 virus strands. Molecular docking calculation have revealed that this type of Ir(III) complex forms stable hydrogen bond and hydrophobic interactions to the major groove of the double helix of HSV. These findings demonstrated (TFPPy)2IrPic and (TFPQ)2IrPic as promising candidates for further evaluation as a novel prodrug platform for combination therapy (RT-CT). © 2020 Elsevier B.V. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
